Shares of Bayer exploded higher on June 25 after the U.S. Supreme Court delivered the ruling the company has sought for years. In a 7-2 decision, the Court shielded Bayer from tens of thousands of claims that Roundup should have carried a cancer warning, throwing out a $1.25 million Missouri verdict.
The majority said consumers cannot sue Bayer for the absence of a cancer label when federal regulators concluded one wasn't necessary. The stock jumped 16% to $45.79, its sharpest single-day gain in years, as analysts rushed to raise targets.
- The Biggest Legal Cloud in Corporate Europe Just Lifted — Partly. Bayer has already settled roughly 100,000 Roundup cases for approximately $11 billion.
About 61,000 active lawsuits remain. The Supreme Court ruling knocks out "failure-to-warn" claims — the most common theory plaintiffs used — but doesn't eliminate every legal avenue. A proposed $7.25 billion settlement for remaining claims received preliminary approval from a Missouri judge , giving Bayer a realistic path to capping total exposure. For shareholders, this means the litigation discount that has crushed the stock since the 2018 Monsanto acquisition is finally shrinking.
- Analysts Are Racing to Catch Up. Major banks including Oddo BHF, Goldman Sachs, UBS, and Barclays have raised price targets, citing restructuring advances and legal milestones.
Oddo BHF upgraded Bayer to "Outperform" and lifted its target to €55 from €39.80.
The consensus rating is now "Buy" from 19 analysts, with an average 12-month target of €49.47 and a high of €60.
- Cash Drain Still Looms Over the Recovery. Bayer expects free cash flow to be negative in 2026 due to roughly €5 billion in lawsuit-related payouts , even as it guides 2026 sales of €44–46 billion and EBITDA of €9.1–9.6 billion.
Net debt stood at €29.8 billion at year-end 2025.
Management has ruled out raising equity and will finance settlements through credit lines, bonds, and structured products.
- Cost Cuts Are Real, But Execution Risks Remain. Bayer has removed six organizational levels, cut management positions by two-thirds, and achieved €1.5 billion in cumulative savings through 2025, targeting €2 billion by year-end 2026.
The company has eliminated 12,000 jobs as part of a $2.3 billion annual savings program. Whether those savings translate into margin improvement or get consumed by settlement cash outflows is the key tension investors must watch through year-end.